Compare Inovio Pharmaceuticals Inc (INO) vs Williams-Sonoma, Inc. (WSM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Williams-Sonoma, Inc. — how do they compare? Inovio Pharmaceuticals Inc trades at $1.09 (market cap $89.27M), while Williams-Sonoma, Inc. trades at $221.87 (market cap $26.30B). The key difference: Williams-Sonoma, Inc. is far larger — about 294.6× Inovio Pharmaceuticals Inc's market cap, and Williams-Sonoma, Inc. pays a 1.36% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| INO | WSM | |
|---|---|---|
Market Cap | $89.27M | $26.30B |
Sector | Health | Consumer Cyclical |
52-Week High | $2.87 | $240.06 |
52-Week Low | $1.05 | $168.64 |
Enterprise Value | $60.28M | $27.14B |
Dividend Yield | — | 1.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.07, down 4.46% today, reflecting persistent bearish technical signals. The company shows minimal revenue of $65.34K (2025) with a net loss of $84.95M, resulting in a negative net margin of 130,000%. Despite beating recent EPS estimates, cash flow remains negative. Key near-term catalyst is the FDA's PDUFA decision on INO-3107 by October 30, 2026.
Outlook hinges on regulatory success for INO-3107; approval could drive significant upside, but failure poses substantial risk. High cash burn and lack of profitability underscore speculative nature. Analyst consensus is cautiously optimistic with 53% buy ratings, yet financial health remains precarious without near-term revenue growth.
Williams-Sonoma (WSM) trades at $223.34, down 2.22% today, with a bullish technical signal from moving averages but neutral oscillators. The company maintains strong profitability with 13.81% net margins and 54.01% ROE, though revenue has declined from $8.7B in 2023 to $7.7B in 2025. Recent earnings beats and consistent dividend payments highlight operational strength amid competitive retail pressures.
WSM presents a mixed outlook with solid fundamentals but faces revenue headwinds and high valuation multiples. Analyst consensus is cautious with 60.72% hold ratings and a $215.22 price target below current levels. Key risks include consumer discretionary spending volatility and execution challenges in maintaining premium positioning against competitors like RH.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Williams-Sonoma, Inc.
With a wide retail and direct-to-consumer presence, Williams-Sonoma is a leader in the $300 billion domestic home category, focused on expanding its exposure in the B2B, marketplace, and franchise areas. Namesake Williams-Sonoma (175 stores) offers high-end cooking essentials, while Pottery Barn (189) provides casual home accessories. Brand extensions include Pottery Barn Kids (52) and PBteen. West Elm (121) is an emerging concept for young professionals, and Rejuvenation (9) offers lighting and house parts. Williams-Sonoma also has a business-to-business team that supports projects that range from residential to large-scale commercial.
Read more on WSM →
